Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) traded today at $2.83, breaking its 52-week low. Approximately 131,000 shares have changed hands today, as compared to an average 30-day volume of 928,000 shares.
There is potential upside of 82.4% for shares of VYNE Therapeutics Inc. based on a current price of $3.01 and an average consensus analyst price target of $5.49.
In the past 52 weeks, shares of VYNE Therapeutics Inc. have traded between the current low of $2.83 and a high of $13.20 and is now at $3.01.
VYNE Therapeutics Inc is a biopharmaceutical company which focuses on the development and commercialization of variety of solutions using its proprietary Molecule Stabilizing Technology. The company is developing products which will help improve lives of the patients with dermatological diseases. Its pipeline includes Amzeeq and Zilxi.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer